Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
about
Investigational dopamine antagonists for the treatment of schizophrenia.A molecular pathway analysis stresses the role of inflammation and oxidative stress towards cognition in schizophrenia.Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients."Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
P2860
Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Emerging pharmacological thera ...... what's different, what's next?
@en
Emerging pharmacological thera ...... what's different, what's next?
@nl
type
label
Emerging pharmacological thera ...... what's different, what's next?
@en
Emerging pharmacological thera ...... what's different, what's next?
@nl
prefLabel
Emerging pharmacological thera ...... what's different, what's next?
@en
Emerging pharmacological thera ...... what's different, what's next?
@nl
P2860
P1433
P1476
Emerging pharmacological thera ...... what's different, what's next?
@en
P2093
Leslie Citrome
P2860
P356
10.1017/S1092852916000729
P577
2016-12-01T00:00:00Z